Cite
HARVARD Citation
Vano, Y. et al. (2022). Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma. Lancet oncology. 23 (7), pp. e318-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Vano, Y. et al. (2022). Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma. Lancet oncology. 23 (7), pp. e318-. [Online].